Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial

2019 ◽  
Vol 108 ◽  
pp. 100-110
Author(s):  
Lorenzo Livi ◽  
Vieri Scotti ◽  
Isacco Desideri ◽  
Calogero Saieva ◽  
Sara Cecchini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Aromatase Inhibitors ◽  
Phase 2 ◽  
Breast Cancer Patients ◽  
Mineral Density ◽  
Single Centre ◽  
The Impact ◽  
Single Blind ◽  
Single Blind Trial

Changes in Bone Mineral Density After Adjuvant Aromatase Inhibitors and Fracture Risk in Breast Cancer Patients

2007 ◽  
Vol 25 (11) ◽  
pp. 1455-1456 ◽  
Author(s):  
Alfredo Berruti ◽  
Marcello Tucci ◽  
Alessandra Mosca ◽  
Federica Vana ◽  
Mara Ardine ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Fracture Risk ◽  
Cancer Patients ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Breast Cancer Patients ◽  
Mineral Density

Five-year follow-up results of aerobic and circuit training on bone mineral density in early breast cancer patients

2020 ◽  
Vol 138 ◽  
pp. S81
Author(s):  
C. Blomqvist ◽  
L. Vehmanen ◽  
H. Sievänen ◽  
P. Kellokumpu-Lehtinen ◽  
R. Nikander ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Bone Mineral ◽  
Breast Cancer Patients ◽  
Mineral Density ◽  
Circuit Training

scholarly journals Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors

2017 ◽  
Vol 13 (5) ◽  
pp. e505-e515 ◽  
Author(s):  
Jamie Stratton ◽  
Xin Hu ◽  
Pamela R. Soulos ◽  
Amy J. Davidoff ◽  
Lajos Pusztai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Early Stage ◽  
Mineral Density ◽  
Dxa Scan ◽  
Bone Mineral Density Testing

Purpose: In postmenopausal women with breast cancer treated with aromatase inhibitors (AIs), most expert panels advise baseline bone mineral density testing with a dual-energy x-ray absorptiometry (DXA) scan repeated every 1 to 2 years. How often this recommendation is followed is unclear. Methods: We performed a retrospective analysis of women with stage I to III breast cancer who started AI therapy from January 1, 2008, to December 31, 2010, with follow-up through December 31, 2012, by using the SEER-Medicare database. Selection criteria included AI use for ≥ 6 months and no recent osteoporosis diagnosis or bisphosphonate use. We used multivariable logistic regression to investigate associations between patient characteristics and receipt of a baseline DXA scan. In patients who continued AI treatment, we assessed rates of follow-up scans. Results: In the sample of 2,409 patients (median age, 74 years), 51.0% received a baseline DXA scan. Demographic characteristics associated with the absence of a baseline DXA scan were older age (85 to 94 years v 67 to 69 years; odds ratio [OR], 0.62; 95% CI, 0.42 to 0.92) and black v white race (OR, 0.68; 95% CI, 0.47 to 0.97). Among patients who underwent a baseline DXA scan and continued AI for 3 years, 28.0% had a repeat DXA scan within 2 years and 65.9% within 3 years. In aggregate, of the 1,164 patients who continued with AI treatment for 3 years, only 34.5% had both a baseline and at least one DXA scan during the 3-year follow-up period. Conclusion: The majority of older Medicare beneficiaries with breast cancer treated with AIs do not undergo appropriate bone mineral density evaluation.

Sign in / Sign up

Export Citation Format

Share Document